ImmunoMet Therapeutics
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to advance novel anti-cancer therapies. Our lead molecule, lixumistat (IM156), is an orally bioavailable small molecule protein complex 1 (PC1) inhibitor that targets Oxidative Phosphorylation (OxPhos) in targeted cancer cells. The company has characterized the safety and biologic activity of lixumistat in Phase 1 studies in healthy subjects and cancer patients. ImmunoMet is currently completing a study of lixumistat in combination with SoC in PDAC patients, with encouraging early results. Finally, WoO and PoC studies of lixumistat in newly-diagnosed OxPhos-dependent GBM patients will initiate in 2026.
ImmunoMet Therapeutics, founded in 2015 as a spin-off from the Korean company HanAll Biopharma, owns a large library of biguanides with the potential for development, internally or with partners, as novel treatments for cancer.
Company HQ City:
Dexter
Company HQ State:
Michigan
Company HQ Country:
United States
Year Founded:
2015
Lead Product in Development:
Lixumistat (IM156), an orally active small molecule inhibitor of Protein Complex 1, the rate limiting step of the Oxidative Phosphorylation pathway.
CEO
Dean Welsch, CEO
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
One, lixumistat
When you expect your next catalyst update?
WoO study to initiate dosing June '26, study completed by October '26.
What is your next catalyst (value inflection) update?
Demonstration of BBB penetration and biological response at the target tissue in a Window-of-Opportunity (WoO) study in newly-diagnosed GBM patients. Subsequently, ImmunoMet will conduct a Phase 2 study comparing lixumistat+SoC to SoC in newly diagnosed biomarker-selected GBM patients.
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}